Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

In the latest close session, Pfizer (PFE) was up +1.12% at $25.18. The stock outpaced the S&P 500's daily gain of 0.19%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Trading at a bit under $25 apiece, Pfizer 's (NYSE: PFE) shares appear tentatively cheap. However, the pharmaceutical giant reached these levels because it has faced significant headwinds, resulting ...

Pfizer delivered strong 3Q25 results, beating EPS and revenue estimates, and raised full-year EPS guidance while maintaining robust cost-saving targets. PFE's $10B acquisition of Metsera secures a ...

Pfizer is buying out Metsera for up to $10 billion after an acquisition battle with another pharma giant. Metsera's leading candidate could be an excellent way for Pfizer to enter the weight-loss drug ...

Pfizer (NYSE:PFE), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60% above ...